Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines

Published:2023-09-07 Issue:5 Volume:52 Page:
ISSN:1107-3756
Container-title:International Journal of Molecular Medicine
language:
Short-container-title:Int J Mol Med

Author:

Chen Xin¹,Gu Jingyao¹,Huang Jiali²,Wen Kang¹,Zhang Ge¹,Chen Zhenyao³,Wang Zhaoxia¹

Affiliation:

1. Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China

2. Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China

3. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China

Publisher

Spandidos Publications

Subject

Genetics,General Medicine

Reference48 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells;Testa;Cancers (Basel),2018

3. Targeting the EGFR T790M mutation in non-small-cell lung cancer;Normanno;Expert Opin Ther Targets,2017

4. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

5. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC;Nagasaka;J Thorac Oncol,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer;Frontiers in Oncology;2024-09-11

2. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC);Molecular Cancer;2024-05-07

3. The emerging role of noncoding RNAs in the EGFR signaling pathway in lung cancer;Pathology - Research and Practice;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3